News | July 02, 2022
Lonza to invest 500 mn in commercial drug product fill & finish facility
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
It is a two dose vaccine to be administered intramuscularly at 28 days apart
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Subscribe To Our Newsletter & Stay Updated
